← Back to Search

HMG-CoA Reductase Inhibitor

Rosuvastatin + Selpercatinib for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-dose up to 72 hours post-dose

Awards & highlights

Study Summary

This trial will test how selpercatinib affects levels of rosuvastatin in healthy people, and how safe and tolerable the combination is. It will last about 26 days.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-dose up to 72 hours post-dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-dose up to 72 hours post-dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose up to 72 hours post-dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-∞]) of Rosuvastatin

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin

Trial Design

1Treatment groups

Experimental Treatment

Group I: Rosuvastatin + SelpercatinibExperimental Treatment2 Interventions

Rosuvastatin administered orally on day 1 followed by rosuvastatin administered with selpercatinib on day 5 orally.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Rosuvastatin

2019

Completed Phase 4

~3150

Selpercatinib

2021

Completed Phase 1

~600

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor

2,618 Previous Clinical Trials

3,201,485 Total Patients Enrolled

Study DirectorEli Lilly and Company

1,347 Previous Clinical Trials

405,679 Total Patients Enrolled

Media Library

Rosuvastatin (HMG-CoA Reductase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05906836 — Phase 1

Healthy Subjects Research Study Groups: Rosuvastatin + Selpercatinib

Healthy Subjects Clinical Trial 2023: Rosuvastatin Highlights & Side Effects. Trial Name: NCT05906836 — Phase 1

Rosuvastatin (HMG-CoA Reductase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05906836 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the research permit persons of advanced age to participate?

"This trial is actively seeking out individuals aged 18 to 65 for enrollment."

Answered by AI

Are there any qualifications that I must fulfil to participate in this research?

"The criteria for eligibility is a healthy body and an age range between 18 to 65. There are currently 28 openings available in this clinical trial."

Answered by AI

Has the FDA certified Rosuvastatin + Selpercatinib for usage?

"Given its designation as a Phase 1 trial, limited safety and efficacy data is available for Rosuvastatin + Selpercatinib resulting in it being assigned a score of 1."

Answered by AI

Is this experiment open to volunteers at the present?

"Per clinicaltrials.gov, this particular trial is not enrolling participants at the moment; it was initially posted on June 16th 2023 and last updated on June 8th 2023. Although this experiment isn't recruiting right now, there are a full 810 other trials actively looking for patients to join them."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

2023. "A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05906836.